Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Declines By 23.7%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,060,000 shares, a decline of 23.7% from the February 13th total of 1,390,000 shares. Approximately 13.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 92,200 shares, the days-to-cover ratio is presently 11.5 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock worth $4,274,000 after acquiring an additional 2,000,000 shares during the period. Jane Street Group LLC grew its stake in shares of Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after buying an additional 543,556 shares during the last quarter. Marshall Wace LLP increased its holdings in Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock worth $1,633,000 after purchasing an additional 319,187 shares in the last quarter. Shay Capital LLC bought a new position in Karyopharm Therapeutics in the 4th quarter valued at approximately $116,000. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $85,000. Institutional investors own 66.44% of the company's stock.

Remove Ads

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI traded up $0.28 on Friday, reaching $6.42. The company had a trading volume of 87,311 shares, compared to its average volume of 74,687. The company's fifty day moving average is $8.74 and its 200-day moving average is $10.73. The firm has a market capitalization of $54.06 million, a price-to-earnings ratio of -6.29 and a beta of 0.11. Karyopharm Therapeutics has a 1-year low of $5.56 and a 1-year high of $24.75.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, research analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Analysts Set New Price Targets

KPTI has been the subject of a number of research reports. Robert W. Baird decreased their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. StockNews.com lowered shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, HC Wainwright boosted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, Karyopharm Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $57.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).